Business Wire

UT-XLEAR

15.8.2022 19:44:10 CEST | Business Wire | Press release

Share
Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection

Xlear has filed an Amended Answer in response to the U.S. Government’s lawsuit against the company. According to Nathan Jones, Xlear’s CEO, the Amended Answer serves three main purposes: First, it provides the Court with still more data that supports the statements Xlear made that nasal hygiene is an additional layer of protection in fighting COVID-19, that our public health officials are ignoring; Second, it lays out in greater detail how the U.S. Government’s lawsuit is an effort to censor science that doesn’t comport with the Government’s vaccine-myopic, failing strategy to combat the disease; Third, it documents how experts, including Dr. Fauci, are increasingly saying the nose is the critical place to fight the virus.

Xlear’s Amended Answer provides two new studies that support the statements Xlear made about the use of its nasal spray as a potential additional layer of protection against COVID-19:

  • A new in vitro study found that use of a simple saline solution stops SAR-CoV2 viral replication in human lung tissue. Rafael R. G. Machado, Talita Glaser, Danielle B. Araujo, Lyvia Lintzmaier Petiz, Danielle B. L. Oliveira, Giuliana S. Durigon, Alessandra L. Leal, João Renato R. Pinho, Luis C. S. Ferreira, Henning Ulrich, Edison L. Durigon, and Cristiane Rodrigues Guzzo, ACS Pharmacology & Translational Science 2021 4 (5), 1514-1527, available at https://pubmed.ncbi.nlm.nih.gov/34651104/ . Nate Jones, CEO of Xlear noted, “The Government agrees, Xlear is a saline nasal solution. This in vitro study documents that saline nasal hygiene helps stop COVID-19 from replicating in nasal tissue—which we know is where the virus typically grows and infects people.”
  • New in silico research determined that compounds of grapefruit seed extract (GSE) were effective inhibitors of the SARS-CoV-2 virus. Belmina Saric, et al., In silico analysis of selected components of grapefruit seed extract SARS-CoV-2 main protease, EuroBiotech J., 5 (special issue 1); 2021, 5. DOI: https://doi.org/10.2478/ebtj-2021-0015 . Most importantly, these experts concluded natural GSE—which is a component of Xlear—was more effective than synthetic versions of the compound.

Jones continued: “These aren’t the Random Clinical Trials the Government is so focused on—but you can’t deny the mounting wall of evidence that nasal hygiene should be used as an additional layer of protection against COVID-19. Moreover, the Government recently announced that it won’t require Random Clinical Trials for the new variant vaccines—that requirement seems to only apply when it is convenient for the Government.”

Jones also noted that the SARS-CoV-2 variants are all strains of coronavirus, and experts have long recommended nasal hygiene to combat coronaviruses. “As a rule, prevention methods and symptom-reduction modalities (e.g., over the counter drugs, handwashing) are not variant specific; they are used against colds and flus on the whole, many caused by coronaviruses. One countermeasure that experts, including the US Government, recommend to fight the common cold, including coronavirus-infections, is nasal hygiene.” DeGeorge KC, Ring DJ, Dalrymple SN. Treatment of the Common Cold. Am Fam Physician. 2019 Sep 1;100(5):281-289. PMID: 31478634, reprinted by NIH as authority at https://pubmed.ncbi.nlm.nih.gov/31478634/ (“Treatments with proven effectiveness for cold symptoms [coronavirus infections] in adults include over-the-counter analgesics, zinc, nasal decongestants . . . The only established safe and effective treatments for children are . . . nasal saline irrigation . . .”). “It’s commonsense, something our Government’s response to COVID seems to be lacking,” Jones added.

As part of its efforts to silence Xlear, the Government asked the Utah Federal Court to preclude Xlear from filing the Amended Answer. The Federal Court ruled in Xlear’s favor. The Court’s ruling specifically noted: “The court shares some concern here, as expressed by Defendants, that the underlying purpose [in the Government’s motion to prevent Xlear’s Amended Answer] is to prevent discovery into disputed facts that may lend support to Defendants’ proposed amendments.” “In other words, the Government is doing everything they can stonewall us from shining a light on their failed COVID-19 response,” Jones added.

“A new more infectious and more dangerous variant is sweeping the nation. Infections are up. Hospitalizations are up. Deaths are up. At the same time, fewer and fewer people are willing to get vaccinated for the third, fourth, who knows how many times,” Jones noted. “It’s obvious we need a new, broader—'vaccine-plus’—approach. But rather than educate people, the Government is suing us in retaliation for talking about the science. I’m deeply afraid even telling the Court about these new studies will bring more Government retaliation, however in the face of the Government’s failure what choice is there. When science gives way to dogma, people suffer,” Jones concluded.

Link:

ClickThru

Social Media:

https://www.facebook.com/xylitol.experts

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NetApp and Elastio Announce Partnership to Deliver Defense-in-Depth Ransomware Resilience24.3.2026 13:00:00 CET | Press release

Robust cyber resilience requires both perimeter defenses and built-in security at the storage layer NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Elastio are helping enterprises enhance their cyber resilience with a layered defense that extends from production storage into recovery data. Security teams must be ready to address threats at every layer of their technology stack, including ransomware that moved quietly through production before it was caught that now lives inside snapshots and backups. Advanced ransomware is engineered to evade prevention tools, moving quietly through production, staying below detection thresholds, reaching backup data before any alert is triggered. "As we migrated our infrastructure, ensuring we had the right level of backup security and assurance was non-negotiable,” Marc Crudgington, VP IT Infrastructure and CISO, Crane WW Logistics. “Elastio provided continuous inspection of our backups from day one - giving us confidence in

NetApp and Commvault Advance Cyber Resilience with Strategic Alliance24.3.2026 13:00:00 CET | Press release

Joint unified cyber resilience solution delivers data security and rapid recovery across hybrid environments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Commvault (NASDAQ: CVLT), a leader in unified resilience at enterprise scale, today announced a strategic alliance to deliver a powerful, integrated solution for enterprise data protection and cyber resilience. The unified solution enables resilience, security, and rapid recovery for customers across on-premises and cloud environments, giving organizations confidence that their data is always available, immutable, and recoverable. “This alliance reinforces NetApp and Commvault’s leadership in the rapidly evolving cyber resilience and data protection market,” said Dallas Olson, Chief Commercial Officer at NetApp. “Together we’re helping customers make their infrastructure intelligent and secure so they have the confidence that their data is always available, protected, and recoverable—no matter where it live

SBC Medical Announces Next-Generation Wellness Strategy “SBC Wellness 2.0”24.3.2026 13:00:00 CET | Press release

Pioneering the “Performance Medicine” category for full-scale entry into the longevity market — targeting a global market projected to reach $2 trillion by 2035 SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced “SBC Wellness 2.0,” a new wellness and longevity platform that combines aesthetic healthcare, preventative care, and data-driven health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323000188/en/ SBC Medical Announces Next-Generation Wellness Strategy “SBC Wellness 2.0” The initiative positions SBC Medical to participate in the fast-growing longevity market, which is projected to reach approximately $800 billion in 2025* and expand to approximately $2 trillion by 2035, with a compound annual growth rate exceeding 10% from 2026 to 2035. Th

Andy Walsky of ExaGrid Honored as A 2026 CRN EMEA Channel Leader24.3.2026 13:00:00 CET | Press release

ExaGrid®, the leader in Tiered Backup Storage, today announced that CRN UK—a brand of The Channel Company—has selected Andy Walsky, VP of EMEA & APAC Sales, for inclusion on the prestigious 2026 CRN® Channel Leaders EMEA list. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324173870/en/ ExaGrid works with resellers and distributors worldwide. The ExaGrid channel programs are designed to be easy for partners, with support from the ExaGrid sales team and without milestone commitments. ExaGrid is known for having a Tiered Backup Storage system that “just works,” is not oversold or undersized, and provides its customers with the best customer support in the industry with an assigned level 2 technical support engineer, ensuring that partners’ customers are well ta

Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights24.3.2026 12:30:00 CET | Press release

COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally well-tolerated and safe profileAcross three large trials in TRD, including two positive Phase 3 studies, COMP360’s differentiated profile is redefining rapidity and durability for TRD patients and demonstrating a consistent level of clinical effect that has never been achieved beforeCompass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4Compass is rapidly advancing commercial readiness plans and expects COMP360 will fit seamlessly across diverse healthcare settings at launchPhase 2b/3 trial in PTSD initiating, following FDA acceptance of IND applicationSuccessful $150 million financing in February and exercise of $200 million in warrants extends cash runway into 2028 Compass Pathways plc (Nasdaq: CMPS), a biote

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye